within Pharmacolibrary.Drugs.ATC.V;

model V03AF01_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.00012,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00061,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 600,            
    Vdp             = 0.00035,
    k12             = 8.1,
    k21             = 8.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AF01_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mesna (sodium 2-mercaptoethane sulfonate) is a uroprotective agent used to reduce the incidence of hemorrhagic cystitis caused by oxazaphosphorine chemotherapy agents such as ifosfamide and cyclophosphamide. It acts by binding toxic urotoxic metabolites in urine, and it is approved and widely used as a supportive care medication during chemotherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration of mesna in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Goren, MP (1992). Oral mesna: a review. <i>Seminars in oncology</i> 19(6 Suppl 12) 65–71. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1485175/&quot;>https://pubmed.ncbi.nlm.nih.gov/1485175</a></p></li><li><p>Goren, MP, et al., &amp; Li, JT (1998). Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 16(2) 616–621. DOI:<a href=&quot;https://doi.org/10.1200/JCO.1998.16.2.616&quot;>10.1200/JCO.1998.16.2.616</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9469350/&quot;>https://pubmed.ncbi.nlm.nih.gov/9469350</a></p></li><li><p>James, CA, et al., &amp; Rogers, HJ (1987). Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. <i>British journal of clinical pharmacology</i> 23(5) 561–568. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1987.tb03092.x&quot;>10.1111/j.1365-2125.1987.tb03092.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3109461/&quot;>https://pubmed.ncbi.nlm.nih.gov/3109461</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AF01_1;
